MA45997A - Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d - Google Patents
Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2dInfo
- Publication number
- MA45997A MA45997A MA045997A MA45997A MA45997A MA 45997 A MA45997 A MA 45997A MA 045997 A MA045997 A MA 045997A MA 45997 A MA45997 A MA 45997A MA 45997 A MA45997 A MA 45997A
- Authority
- MA
- Morocco
- Prior art keywords
- disease
- methods
- treating crohn
- nkg2d antibody
- nkg2d
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662377358P | 2016-08-19 | 2016-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA45997A true MA45997A (fr) | 2019-06-26 |
Family
ID=61197073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045997A MA45997A (fr) | 2016-08-19 | 2017-08-17 | Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d |
Country Status (9)
Country | Link |
---|---|
US (1) | US20190292265A1 (fr) |
EP (1) | EP3500293A4 (fr) |
JP (1) | JP2019528285A (fr) |
KR (1) | KR20190038919A (fr) |
AU (1) | AU2017312049A1 (fr) |
CA (1) | CA3034324A1 (fr) |
MA (1) | MA45997A (fr) |
MX (1) | MX2019001958A (fr) |
WO (1) | WO2018035330A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021525243A (ja) | 2018-05-21 | 2021-09-24 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | Nk細胞による標的細胞の殺傷を増進するための組成物および方法 |
CN113166762A (zh) | 2018-12-21 | 2021-07-23 | 欧恩科斯欧公司 | 新的偶联核酸分子及其用途 |
WO2021057988A1 (fr) * | 2019-09-27 | 2021-04-01 | 廖睿 | Utilisation de réactif pour détecter la teneur en calprotectine fécale dans la préparation d'un kit pour le criblage de lésions des trompes de fallope |
AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
CN116199777A (zh) * | 2021-12-01 | 2023-06-02 | 北京免疫方舟医药科技有限公司 | 抗hNKG2D抗体及其应用 |
IL313439A (en) | 2021-12-16 | 2024-08-01 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005082110A2 (fr) * | 2004-02-26 | 2005-09-09 | Illumina Inc. | Marqueurs haplotypes pour le diagnostic de la susceptibilite aux conditions immunologiques |
BRPI0821658B8 (pt) * | 2007-12-14 | 2021-05-25 | Novo Nordisk As | anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos |
MX2012001333A (es) * | 2009-07-30 | 2012-06-01 | Teva Pharma | Tratamiento de la enfermedad de crohn con la laquinimod. |
EP2519653A4 (fr) * | 2009-12-31 | 2013-07-10 | Univ Columbia | Procédés pour la détection et la régulation de l'alopécie en aires, et de cohortes de gènes de celle-ci |
WO2016120217A1 (fr) * | 2015-01-26 | 2016-08-04 | Cellectis | Récepteurs d'antigènes chimériques (car) spécifiques anti-hsp70 pour une immunothérapie anticancéreuse |
-
2017
- 2017-08-17 CA CA3034324A patent/CA3034324A1/fr not_active Abandoned
- 2017-08-17 AU AU2017312049A patent/AU2017312049A1/en not_active Abandoned
- 2017-08-17 KR KR1020197007550A patent/KR20190038919A/ko not_active Application Discontinuation
- 2017-08-17 MA MA045997A patent/MA45997A/fr unknown
- 2017-08-17 WO PCT/US2017/047357 patent/WO2018035330A1/fr unknown
- 2017-08-17 JP JP2019509555A patent/JP2019528285A/ja active Pending
- 2017-08-17 EP EP17842125.1A patent/EP3500293A4/fr not_active Withdrawn
- 2017-08-17 US US16/325,969 patent/US20190292265A1/en not_active Abandoned
- 2017-08-17 MX MX2019001958A patent/MX2019001958A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20190292265A1 (en) | 2019-09-26 |
EP3500293A1 (fr) | 2019-06-26 |
JP2019528285A (ja) | 2019-10-10 |
KR20190038919A (ko) | 2019-04-09 |
AU2017312049A1 (en) | 2019-02-21 |
CA3034324A1 (fr) | 2018-02-22 |
WO2018035330A1 (fr) | 2018-02-22 |
EP3500293A4 (fr) | 2020-08-19 |
MX2019001958A (es) | 2019-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45997A (fr) | Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d | |
MA51631A (fr) | Anticorps anti-pd1 et méthodes de traitement | |
MA54132A (fr) | Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23 | |
MA47206A (fr) | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 | |
MA51815A (fr) | Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp | |
MA52789A (fr) | Méthodes de traitement du cancer avec des anticorps anti-pd-1 | |
MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
MA45192A (fr) | Traitement d'association | |
MA41028A (fr) | Méthodes et formulations pour le traitement de pathologies oculaires vasculaires | |
MA45149A (fr) | Méthodes de traitement de la maladie d'alzheimer | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA43982A (fr) | Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1 | |
EA201990778A1 (ru) | Анти-il-33 антитела и их применение | |
MA46842A (fr) | Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 | |
EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
DK3405215T3 (da) | Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser | |
MX2022010809A (es) | Antagonistas de integrina-beta7 para usarse en el tratamiento y diagnostico de trastornos inflamatorios gastrointestinales. | |
MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
MA53329A (fr) | Méthodes de traitement de l'épilepsie | |
MA47362A (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif | |
MA47395A (fr) | Méthode pour le traitement d'une maladie neurologique | |
MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
MA46353A (fr) | Méthodes de traitement de l'infertilité féminine | |
MA51678A (fr) | Méthodes de traitement de l'amyotrophie musculaire |